Guardant Health’s Shield Blood Test Gains EviCore Coverage, Expanding Access to Colorectal Cancer Screening
Guardant Health, a precision oncology company focused on advancing cancer detection and treatment through blood-based technologies, has announced a significant expansion in commercial coverage for its Shield™ blood test for colorectal cancer (CRC) screening. Under an updated policy, Shield will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, in accordance with American Cancer Society (ACS) guidelines.
The policy change represents another important milestone in the commercial adoption of Shield, which has emerged as a major blood-based option for colorectal cancer screening. EviCore, a Cigna-owned company and the second-largest specialty benefits manager in the United States, provides medical benefit management services to Blue Cross Blue Shield plans and other commercial payers across the country.
The new coverage is expected to broaden access to Shield for eligible adults and further strengthen the role of blood-based screening in efforts to improve colorectal cancer detection. The policy applies to payers across 23 states, creating an additional pathway for average-risk adults aged 45 and older to access the test.
EviCore Coverage Expands Shield’s Commercial Reach
Guardant Health said the latest policy update comes amid rapid growth in commercial adoption of Shield. Over the most recent fiscal quarter, the company has secured meaningful additional coverage from major healthcare organizations, including Carelon, described as the largest specialty benefits manager in the United States, and UnitedHealth Group, the country’s largest insurer.
With these coverage developments, the total number of covered lives for Shield has increased to approximately 94 million.
The expansion is particularly significant because access to colorectal cancer screening remains a major public health priority. Colorectal cancer is one of the most common cancers, and screening can help identify cancer earlier, when treatment may be more effective. However, participation in screening remains an ongoing challenge, making the availability of additional screening options important for patients who may not complete conventional screening methods.
Shield provides a blood-based alternative for average-risk adults. Guardant Health describes it as the leading blood test for colorectal cancer screening and the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults.
The updated EviCore policy will take effect January 1, 2027, bringing Shield into the clinical guidelines used in the company’s coverage framework.
Addressing the Need for More Accessible Screening
Colorectal cancer screening has traditionally relied on several established approaches, including stool-based tests and visual examinations such as colonoscopy. While these approaches remain important tools for detecting colorectal cancer, adherence to screening recommendations can vary among patients.
A blood-based screening option provides another approach for individuals who may be reluctant or unable to complete other screening methods. Guardant Health’s Shield test is designed to make screening more convenient by using a blood sample collected during a routine healthcare visit.
The company believes this convenience can help address one of the central challenges in colorectal cancer prevention: getting eligible adults to complete recommended screening.
The need for improved screening access is particularly important as colorectal cancer rates have been increasing among adults younger than 65, according to the information provided by Guardant Health. The company also highlighted increasing mortality among younger adults, with colorectal cancer identified as the leading cause of cancer death among people under age 50.
Against this backdrop, expanding access to an FDA-approved blood-based screening option could help healthcare providers offer another pathway for patients who are due for screening.
Guardant Health Highlights Clinical Validation
Guardant Health said Shield has demonstrated strong performance in colorectal cancer detection across all stages compared with published performance for fecal immunochemical testing (FIT).
The test is recommended in both American Cancer Society and National Comprehensive Cancer Network guidelines, providing support for its use within current colorectal cancer screening recommendations.
The inclusion of Shield in clinical guidelines is an important component of the test’s broader commercial adoption. Clinical recommendations can help healthcare professionals understand where a screening technology fits within established care pathways while also supporting discussions between providers and patients about appropriate screening options.
Shield has also accumulated substantial real-world experience. According to Guardant Health, more than 200,000 Shield tests have been performed in real-world settings.
The company said these real-world results demonstrate that Shield can significantly increase overall colorectal cancer screening completion among patients who are due for screening across different practice and health system environments.
Guardant Health reported screening adherence of more than 90% among patients using Shield in these settings.
These findings are particularly relevant because the effectiveness of any screening strategy depends not only on the test’s clinical performance but also on whether patients actually complete the screening process. By offering a blood-based option that can be incorporated into healthcare visits, Shield is intended to make screening easier to complete for eligible individuals.
Major Payer Expansion Supports Adoption
The addition of EviCore coverage follows a series of developments that have expanded the commercial reach of Shield.
Carelon and UnitedHealth Group have also provided meaningful coverage expansion, contributing to the company’s growth in covered lives. Together with the latest EviCore policy, these developments demonstrate increasing interest among major healthcare organizations in blood-based approaches to colorectal cancer screening.
Guardant Health said the cumulative effect of these coverage decisions has brought Shield’s total covered lives to approximately 94 million.
For a diagnostic test, broad insurance coverage can be an important factor in determining whether patients can access and routinely use the technology. Coverage can also help healthcare providers integrate new screening options into clinical workflows with greater confidence that eligible patients will have a pathway to reimbursement.
The EviCore policy is particularly significant because EviCore operates across multiple states and manages medical benefits for commercial payers, including Blue Cross Blue Shield organizations and other insurers.
The updated Shield policy will affect payers in 23 states.
Coverage Across 23 States
The EviCore policy impacts payers in Arkansas, Alabama, Connecticut, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland and Washington, D.C., Maine, Missouri, Minnesota, North Carolina, Nevada, New York, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Wisconsin, Wyoming and West Virginia.
This geographic reach provides Shield with access to a broad commercial payer population.
For Guardant Health, the policy expansion also reinforces its strategy of increasing access to blood-based cancer screening through partnerships and coverage decisions involving major healthcare organizations.
As more insurers and specialty benefits managers incorporate Shield into their coverage frameworks, the company expects the test to become increasingly accessible to eligible patients.
CEO Calls Coverage a Critical Milestone
AmirAli Talasaz, co-CEO of Guardant Health, described the EviCore coverage decision as an important milestone in the company’s commercial expansion.
“With the latest coverage from EviCore, an overwhelming majority of eligible Americans now have access to the most clinically-validated blood-based colorectal cancer screening option,” Talasaz said.
He added that the expanded coverage represents another important step in the company’s broader efforts to increase adoption among insurers and improve access to screening.
“Today’s expanded coverage from EviCore marks another critical milestone in our commercial expansion and rapid adoption by insurers as part of our broader mission to make screening more accessible for those who need it most,” Talasaz said.
The comments underscore Guardant Health’s focus on making blood-based screening a more widely available component of colorectal cancer prevention and early detection.
Importance of Screening for Average-Risk Adults
The Shield test is intended for average-risk adults, with the latest EviCore coverage applying to individuals aged 45 and older who meet the applicable screening criteria.
The age threshold is significant because colorectal cancer screening recommendations have increasingly emphasized screening beginning at age 45 for average-risk adults. Earlier screening can provide an opportunity to identify colorectal cancer or precancerous disease before symptoms become apparent.
For healthcare providers, having multiple screening options can make it easier to tailor screening discussions to individual patients. Some patients may prefer a blood-based test because of its convenience, while others may choose established stool-based testing or colonoscopy based on their personal circumstances and clinical recommendations.
The availability of Shield does not eliminate the importance of other screening methods. Instead, the blood test provides an additional option within the broader colorectal cancer screening landscape.
Real-World Evidence Supports Screening Completion
Guardant Health’s emphasis on real-world use is another important element of the announcement.
More than 200,000 Shield tests have reportedly been performed in real-world settings. According to the company, the experience demonstrates that the test can increase overall screening completion among patients who are due for colorectal cancer screening.
The reported screening adherence of more than 90% highlights the potential impact of convenience on patient participation.
Screening programs can face challenges when patients delay or avoid recommended procedures. By incorporating blood collection into a healthcare encounter, a blood-based screening test can potentially reduce some of the logistical barriers associated with completing screening.
For health systems and medical practices, this may also create an opportunity to integrate colorectal cancer screening into routine workflows and identify patients who are due for testing.
Expanding the Role of Blood-Based Cancer Detection
Guardant Health has built its business around precision oncology and the use of blood-based technologies to support cancer detection and treatment. The commercial expansion of Shield represents an extension of this strategy into population-level cancer screening.
The company’s focus on colorectal cancer screening reflects the potential role of liquid biopsy and other blood-based technologies in making cancer detection more accessible.
The EviCore policy decision also comes at a time when healthcare organizations are increasingly evaluating technologies that can improve screening participation while maintaining clinically meaningful performance.
For Guardant Health, the combination of regulatory approval, guideline recommendations, real-world experience and expanding payer coverage provides an increasingly broad foundation for Shield adoption.
The new EviCore coverage will become effective January 1, 2027, marking another step in the commercial rollout of Shield.
With approximately 94 million covered lives following recent coverage expansions, Guardant Health is positioning Shield as an increasingly accessible screening option for eligible average-risk adults.
The addition of EviCore further expands the number of commercial payers that can provide coverage for the test, while the policy’s reach across 23 states increases geographic access.
As colorectal cancer continues to pose a significant health challenge, particularly amid rising rates among younger adults, improving screening participation remains a key objective for healthcare providers, insurers and diagnostic companies.
Guardant Health’s latest coverage announcement illustrates how payer adoption can influence the availability of emerging diagnostic technologies. By securing coverage from major specialty benefits managers and insurers, the company is seeking to move Shield from a newly introduced diagnostic technology toward a more established option within routine colorectal cancer screening.
The company will continue to build on its growing commercial footprint, real-world testing experience and guideline support as it works to expand access to blood-based colorectal cancer screening.
For patients aged 45 and older who are at average risk of colorectal cancer, the EviCore policy represents an additional potential pathway to recommended screening beginning in 2027. For healthcare systems and providers, the expanded coverage provides another tool to engage patients who may otherwise delay or avoid screening.
Ultimately, Guardant Health’s strategy centers on making colorectal cancer screening easier to access and complete. The company’s latest coverage expansion with EviCore, together with recent decisions involving other major healthcare organizations, represents a significant step toward that goal and further establishes blood-based screening as an important component of the evolving colorectal cancer screening landscape.
Source link: https://investors.guardanthealth.com/
